Yaz and Yasmin birth control pills linked to increased IBS risk in Canadian study

by John Chapman

A study conducted by researchers with the University of British Columbia has found that patients taking the birth control drugs Yaz and Yasmin may be more likely to develop irritable bowel syndrome (IBS). According to results published in the journal Current Drug Safety, patients taking Yaz, Yasmin, or other birth control drugs containing the hormone drospirenone were 63% more likely to develop IBS than patients taking another type of birth control.

The Canadian study is not the first to uncover an increased risk of side effects from Yaz and Yasmin compared to other birth control products. According to two studies published in the British Medical Journal (BMJ), women taking Yaz or Yasmin are twice as likely to suffer blood clots as women who are prescribed other types of birth control. This increased blood clot risk can expose patients to a number of other potential and serious side effects, including deep vein thrombosis (DVT), pulmonary embolism (PE), heart attack, or stroke.

These studies and others like them have prompted the Food and Drug Administration to warn women about the risk of blood clots and other side effects they may face by taking drospirenone-containing birth control pills such as Yaz and Yasmin. Despite the FDA’s Yasmin and Yaz warning, the agency has not announced any plans to issue a recall of any drospirenone birth control products.

Over 11,000 Yasmin and Yaz lawsuits have already been filed by patients who suffered blood clots or other side effects from the birth control pills. Three Yasmin and Yaz class action lawsuits have also been filed by patients in the U.S., as well as another on behalf of patients in Canada.

If you or a loved one used Yaz or Yasmin and suffered blood clots or other serious side effects, contact the law firm of Heygood, Orr & Pearson for a free evaluation of your case. You can reach us by calling toll-free at 1-877-446-9001, or by filling out our free online case evaluation form.